NADMED, a Finland-based biotechnology company specializing in blood testing technology, has successfully raised €3.5 million in funding. This financial boost will facilitate the company’s expansion into the U.S. and other global markets. The funding round was spearheaded by Nordic Science Investments (NSI), with additional contributions from previous backers, including Voima Ventures, University of Helsinki Funds, and private European investors, as well as a grant from Business Finland.
NADMED’s innovative technology measures all four forms of vitamin B3 and glutathiones directly from fresh blood samples. This data aids in identifying deficiencies and preventing diseases. In recent years, the biotechnology industry has witnessed a surge in demand for reliable testing methods due to increasing evidence linking NAD and glutathione levels to various health conditions. NADMED’s technology, which delivers results in hours, stands out for its speed and accuracy compared to traditional methods.
Expanding Market Reach
The new funds will primarily support NADMED’s expansion into the U.S. and other international markets. This strategic move is aimed at addressing the rising demand from clinicians and the pharmaceutical industry for quick and reliable testing methods. NADMED’s CEO and co-founder, Jari Närhi, emphasized the significant role metabolism will play in personalized medicine, stating,
“In the coming years, metabolism will be the hottest topic in medicine and biology, especially when applied to personalized health and disease understanding. In this dawning age of metabolism, NAD will be the new DNA.”
NADMED’s proprietary technology, developed from years of research at the University of Helsinki, utilizes a colorimetric quantification method to measure NAD levels accurately and efficiently. This approach has proven to be as precise as mass spectrometry but significantly quicker, providing an invaluable tool for clinical laboratories and research institutions. The company’s mission is to bring new capabilities to diagnostics and personalized medicine, ultimately advancing metabolic science.
Healthcare Implications
Accurate measurement of NAD and glutathione levels is crucial, as imbalances can be linked to numerous age-related health conditions. Poor diet, post-inflammatory states, and treatment side effects can also impact NAD levels. Identifying and correcting these imbalances could lead to improved outcomes in conditions such as metabolic disorders, cancer, heart and brain diseases, and muscle atrophy. Alexandra Gylfe, Founding Partner at NSI, highlighted the significance of NADMED’s technology,
“Investing in NADMED was a compelling choice for us, driven by the exceptional expertise of Professor Anu Suomalainen Wartiovaara, a globally recognized leader in metabolic disorders.”
NADMED’s testing methods are poised to revolutionize the healthcare sector, offering more precise treatment options. The ability to measure NAD and glutathione levels swiftly and accurately could lead to better-targeted drug administration based on an individual’s metabolic profile. This advancement holds promise for more personalized and effective treatments in the future.
The successful funding round signals strong investor confidence in NADMED’s technology and its potential impact on personalized medicine. The expansion into the U.S. market will not only enhance the company’s global footprint but also drive further innovation in metabolic science. The collaboration with NSI and other investors will provide NADMED with the resources needed to improve diagnostics, therapy monitoring, and personalized treatments on a global scale.
As the healthcare industry increasingly focuses on personalized medicine, NADMED’s advancements in NAD and glutathione measurement technology are set to play a pivotal role. By enabling quick and accurate testing, the company is positioned to meet the growing demand for reliable diagnostic tools. This, in turn, will facilitate better patient outcomes and propel the next wave of innovation in metabolic science.
